Phase II trial of edatrexate in patients with metastatic colorectal cancer

Gerald H. Clamon, Charles E. Riggs, Robert Dreicer, Raymond Hohl

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

Original languageEnglish (US)
Pages (from-to)359-361
Number of pages3
JournalInvestigational New Drugs
Volume13
Issue number4
DOIs
StatePublished - Dec 1 1995

Fingerprint

Colorectal Neoplasms
Colonic Neoplasms
Heterografts
Nude Mice
Human Activities
Methotrexate
Appointments and Schedules
Drug Therapy
edatrexate
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Molecular Medicine

Cite this

Clamon, Gerald H. ; Riggs, Charles E. ; Dreicer, Robert ; Hohl, Raymond. / Phase II trial of edatrexate in patients with metastatic colorectal cancer. In: Investigational New Drugs. 1995 ; Vol. 13, No. 4. pp. 359-361.
@article{4f49ef19f2bf47b0b990828e6f4a7ad3,
title = "Phase II trial of edatrexate in patients with metastatic colorectal cancer",
abstract = "Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.",
author = "Clamon, {Gerald H.} and Riggs, {Charles E.} and Robert Dreicer and Raymond Hohl",
year = "1995",
month = "12",
day = "1",
doi = "10.1007/BF00873145",
language = "English (US)",
volume = "13",
pages = "359--361",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Phase II trial of edatrexate in patients with metastatic colorectal cancer. / Clamon, Gerald H.; Riggs, Charles E.; Dreicer, Robert; Hohl, Raymond.

In: Investigational New Drugs, Vol. 13, No. 4, 01.12.1995, p. 359-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of edatrexate in patients with metastatic colorectal cancer

AU - Clamon, Gerald H.

AU - Riggs, Charles E.

AU - Dreicer, Robert

AU - Hohl, Raymond

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

AB - Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

UR - http://www.scopus.com/inward/record.url?scp=0029582628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029582628&partnerID=8YFLogxK

U2 - 10.1007/BF00873145

DO - 10.1007/BF00873145

M3 - Article

C2 - 8824357

AN - SCOPUS:0029582628

VL - 13

SP - 359

EP - 361

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -